Alpha Cognition Inc (TSE:ACOG) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Alpha Cognition Inc. has released promising interim preclinical data for its drug ALPHA-1062, aimed at treating mild traumatic brain injuries caused by repetitive blast trauma, a common military injury. The study, supported by the US Department of Defense, shows that ALPHA-1062 reduces neuroinflammation and neuropathology in the brain. This progress signals a potential breakthrough in treating brain injuries related to military service.
For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue